MedTrace Logo

Flupenthixol and Haloperidol for Treating Cocaine Abuse Schizophrenics - 9

NCT00000274 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2017-01-12

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of flupenthixol and haloperidol for cocaine dependence in individuals with schizophrenia/schizoaffective illness.

Conditions

  • Cocaine-Related Disorders
  • Substance-Related Disorders

Interventions

DRUG

Flupenthixol

Sponsors & Collaborators

  • New York State Psychiatric Institute

    collaborator OTHER

  • National Institute on Drug Abuse (NIDA)

    lead NIH

Principal Investigators

  • Herbert Kleber, M.D. · New York State Psychiatric Institute

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-03-31
Completion
1999-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000274 on ClinicalTrials.gov